PhaseBio Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiovascular diseases. The company's lead program was a ticagrelor reversal agent leveraging its proprietary ELP (elastin-like polypeptide) drug delivery platform. PhaseBio filed for Chapter 11 bankruptcy protection in October 2022 after its lead cardiovascular drug candidate failed to meet its primary endpoint in a pivotal clinical trial.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account